CALGARY, AB,
March 23, 2022 /CNW/ -
Universal Ibogaine Inc. (TSXV: IBO) and (OTCQB: IBOGF) ("UI" or the
"Company") a life sciences company with a mission to transform the
world of addiction treatment through medicalized ibogaine and a
state of the art ongoing care program, is pleased to announce the
key strategic addition of Julie
Dumouchel as Director of Clinical Trials. Universal
Ibogaine is working towards a planned clinical trial with Health
Canada to prove the safety and efficacy of ibogaine for the
disruption of opioid addiction. UI owns the global licensing
rights for the ibogaine treatment protocol developed by Dr.
Alberto Sola, UI Board Member and
one of the founders of the Clear Sky Recovery Clinic which has
operated an addiction treatment centre in Cancun, Mexico since 2007. Dr Sola has
safely administered over 3,700 ibogaine treatments, more than any
other doctor in the world.
Julie Dumouchel brings 25 years
in the pharmaceutical industry, where she has held various clinical
research roles, developing a deep understanding of the drug
development process. Julie is passionate about clinical operations
and the drug development process. Her experience leading
strong research teams to advance clinical trials while navigating
changing regulations will augment UI's planned business platforms
of drug development and clinical service delivery.
As Director of Clinical Trials, Julie
Dumouchel will lead the design, planning and execution of
ibogaine clinical trials and related projects. As a pharmaceutical
industry executive, Julie has had roles in Clinical Research
Organizations such as Quintiles and Santé Cannabis, biotechs
including MethylGene (TSX: MYG), Canopy Health Innovations and
large pharmaceutical companies including Schering-Plough, Merck,
and Bayer. In 2018, as the Director of Clinical Operations at
Canopy Health Innovation, Julie assembled a clinical operations
team to advance key trials using medical cannabis while navigating
an environment of complex and changing regulations. In her role at
Santé Cannabis, Julie led the team responsible for all aspects of
clinical trials (medical cannabis and psychedelics), from planning
to reporting while maintaining high quality standards.
Nick Karos, UI CEO stated, "We
welcome Julie to our team, and look forward to her guidance as we
continue to work with our CRO research partners to finalize our
Clinical Trial Application for Health Canada. This
announcement demonstrates we are making progress towards our CTA
and confident in our path forward."
About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the
safety and efficacy of its ibogaine based drug detox protocol
through a planned Canadian Clinical Trial, and ultimately to
utilize that protocol globally through future licensing
agreements. UI is concurrently developing a state of the art
holistic addiction treatment protocol at its Kelburn Recovery
Centre in Winnipeg, Manitoba that,
when paired with the planned ibogaine detox protocol, is intended
to revolutionize the way we treat addiction and drastically improve
the lives of individuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This news release may contain forward-looking statements and
information. Forward-looking information is frequently
characterized by words such as "plans", "expect", "project",
"intend", "will", "believe", "anticipate", "estimate", "scheduled",
"potential", or other similar words, or statements that certain
events or conditions "may", "should" or "could" occur. The
forward-looking statements and information are based on certain key
expectations and assumptions made by UI. Although UI
believes that the expectations and assumptions on which the
forward-looking statements are based are reasonable, undue
reliance should not be placed on the forward-looking statements
because UI can give no assurance that they will prove to be
correct.
Since forward-looking statements address future events and
conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those
currently anticipated due to a number of factors and risks, which
include, but are not limited to, risks that required regulatory
approvals are not obtained. The reader is cautioned that
assumptions used in the preparation of such information, although
considered reasonable by UI at the time of preparation, may prove
to be incorrect and readers are cautioned not to place undue
reliance on forward-looking information, which speaks only to
conditions as of the date hereof. UI does not undertake any
obligation to release publicly any revisions to forward-looking
information contained herein to reflect events or circumstances
that occur after the date hereof or to reflect the occurrence of
unanticipated events, except as may be required under applicable
securities laws.
Related Links
https://universalibogaine.com
SOURCE Universal Ibogaine Inc.
